Cochrane · systematic review · CD008766
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer
Patel, A, Kalachand, R, Busschots, S, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
25
current version
GRADE rated
19
No studies
6
Included studies
NR
No studies 6 · 24%Ungraded 0 · 0%Very low 8 · 32%Low 10 · 40%Moderate 1 · 4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Weekly paclitaxel compared to three‐weekly paclitaxel for the treatment of recurrent epithelial ovarian cancer
Population: women with recurrent epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Weekly paclitaxel vs three‐weekly paclitaxel | HR 0.94 [0.66, 1.33] | 2 studies · 263 participants | Very low Downgraded: imprecision |
Response rate Weekly paclitaxel vs three‐weekly paclitaxel | RR 1.07 [0.78, 1.48] | 2 studies · 263 participants | Very low Downgraded: imprecision |
Response rate ‐ platinum‐sensitive Weekly paclitaxel vs three‐weekly paclitaxel | RR 1.13 [0.77, 1.65] | 2 studies · 100 participants | Very low Downgraded: imprecision |
Response rate ‐ platinum‐resistant Weekly paclitaxel vs three‐weekly paclitaxel | RR 1.01 [0.55, 2.12] | 2 studies · 163 participants | Very low Downgraded: imprecision |
Quality of Life ‐ not reported Weekly paclitaxel vs three‐weekly paclitaxel | no estimate extracted | NR | No studies |
Progression‐free survival Weekly paclitaxel vs three‐weekly paclitaxel | HR 0.83 [0.46, 1.52] | 2 studies · 263 participants | Very low Downgraded: imprecision |
Neurotoxicity Weekly paclitaxel vs three‐weekly paclitaxel | RR 0.53 [0.19, 1.48] | 2 studies · 260 participants | Very low Downgraded: imprecision, inconsistency |
Neutropenia Weekly paclitaxel vs three‐weekly paclitaxel | RR 0.51 [0.27, 0.95] | 2 studies · 260 participants | Low Downgraded: imprecision, inconsistency |
Alopecia Weekly paclitaxel vs three‐weekly paclitaxel | RR 0.58 [0.46, 0.73] | 1 study · 205 participants | Low Downgraded: imprecision, inconsistency |
175 mg/m2 paclitaxel compared to 250 mg/m2 paclitaxel for the treatment of recurrent epithelial ovarian cancer
Population: women with recurrent epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival 175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel | HR 0.97 [0.77, 1.23] | 1 study · 330 participants | Low Downgraded: imprecision |
Response rate 175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel | RR 0.86 [0.4, 1.89] | 1 study · 265 participants | Very low Downgraded: imprecision |
Response rate ‐ platinum‐sensitive 175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel | RR 0.6 [0.39, 0.93] | 1 study · 213 participants | Low Downgraded: imprecision |
Response rate ‐ platinum‐resistant 175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel | RR 1.34 [0.7, 2.57] | 1 study · 52 participants | Very low Downgraded: imprecision |
Quality of Life ‐ not measured 175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel | no estimate extracted | NR | No studies |
Progression‐free survival 175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel | HR 1.07 [0.88, 1.3] | 1 study · 330 participants | Low Downgraded: imprecision |
Neurotoxicity 175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel | RR 0.41 [0.21, 0.8] | 1 study · 330 participants | Moderate Downgraded: imprecision |
Neutropenia 175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel | RR 1.14 [0.74, 1.74] | 1 study · 330 participants | Low Downgraded: imprecision |
Alopecia ‐ not reported 175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel | no estimate extracted | NR | No studies |
135 mg/m2 paclitaxel compared to 175 mg/m2 paclitaxel for the treatment of recurrent epithelial ovarian cancer
Population: women with recurrent epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival 135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel | HR 0.96 [0.77, 1.19] | 1 study · 407 participants | Low Downgraded: imprecision |
Response rate 135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel | RR 0.75 [0.48, 1.17] | 1 study · 382 participants | Low Downgraded: imprecision |
Quality of Life ‐ not measured 135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel | no estimate extracted | NR | No studies |
Progression‐free survival 135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel | HR 1.09 [0.94, 1.28] | 1 study · 407 participants | Low Downgraded: imprecision |
Neurotoxicity 135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel | RR 0.19 [0.01, 3.99] | 1 study · 391 participants | Low Downgraded: imprecision |
Neutropenia ‐ not reported 135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel | no estimate extracted | NR | No studies |
Alopecia ‐ not measured 135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel | no estimate extracted | NR | No studies |